Bayer’s ambitions boosted by relaxation of EU gene-edited crop rules
German life sciences giant says looser regulations could reshape Europe’s €6bn seed market
Related reading
Brussels backs softer regime for gene-edited plants
Agreement over lighter-touch regulation marks first big loosening of rules since ‘Frankenfoods’ outcry 20 years ago
Bayer soars on promising trial results for stroke prevention drug
Findings are respite for German conglomerate facing sliding sales of blockbuster drugs and US legal challenges
US Supreme Court to hear Bayer’s appeal against weedkiller lawsuits
German group is seeking to end multibillion-dollar litigation alleging its Roundup pesticide causes cancer
Europe’s pharma industry risks lagging behind US and China, says German…
Boehringer Ingelheim says pricing regime hinders access to treatments as group touts liver benefits from weight-loss drug
EU says ‘forever chemicals’ ban could save €110bn by 2050
European Commission considers broad restrictions on substances linked to cancer and infertility
The EU’s capital market strategy must support innovation
Rather than pursuing grand institutional designs, pragmatic steps are needed to unlock capital to boost growth